Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Significant Drop in Short Interest

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCTGet Free Report) was the target of a significant drop in short interest during the month of February. As of February 29th, there was short interest totalling 4,220,000 shares, a drop of 6.6% from the February 14th total of 4,520,000 shares. Based on an average daily volume of 419,100 shares, the short-interest ratio is presently 10.1 days. Currently, 17.3% of the company’s shares are sold short.

Analysts Set New Price Targets

A number of equities analysts recently commented on ARCT shares. HC Wainwright reissued a “buy” rating and issued a $51.00 price objective on shares of Arcturus Therapeutics in a research note on Tuesday, November 28th. Canaccord Genuity Group assumed coverage on shares of Arcturus Therapeutics in a research report on Wednesday, December 13th. They issued a “buy” rating and a $90.00 price objective for the company. Citigroup upped their price objective on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a research report on Thursday, February 8th. Canaccord Genuity Group initiated coverage on shares of Arcturus Therapeutics in a research report on Wednesday, December 13th. They set a “buy” rating for the company. Finally, William Blair restated an “outperform” rating on shares of Arcturus Therapeutics in a report on Friday, March 8th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Arcturus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $56.43.

View Our Latest Report on ARCT

Arcturus Therapeutics Price Performance

Shares of NASDAQ ARCT opened at $33.13 on Tuesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.49 and a quick ratio of 4.49. Arcturus Therapeutics has a 1-year low of $14.62 and a 1-year high of $43.81. The business has a 50-day moving average of $36.09 and a 200-day moving average of $29.25. The company has a market capitalization of $885.23 million, a price-to-earnings ratio of -31.86 and a beta of 2.64.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARCT. Blair William & Co. IL purchased a new stake in shares of Arcturus Therapeutics in the third quarter valued at $478,000. Schonfeld Strategic Advisors LLC acquired a new stake in Arcturus Therapeutics during the third quarter worth about $2,738,000. AQR Capital Management LLC grew its position in Arcturus Therapeutics by 239.8% during the third quarter. AQR Capital Management LLC now owns 172,202 shares of the biotechnology company’s stock worth $4,400,000 after buying an additional 121,526 shares in the last quarter. Stratos Wealth Partners LTD. bought a new position in Arcturus Therapeutics during the third quarter worth about $301,000. Finally, Jupiter Asset Management Ltd. bought a new position in Arcturus Therapeutics during the third quarter worth about $4,977,000. 88.87% of the stock is owned by institutional investors.

Arcturus Therapeutics Company Profile

(Get Free Report)

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

Recommended Stories

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.